AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 241 min read$PHVS

Schikan Johannes Gerardus Christiaan Petrus sold $29K of PHVS

Schikan Johannes Gerardus Christiaan Petrus sold 800 shares of Pharvaris N.V. (PHVS) at $36.19 on 2026-09-22.

Original reporting
SEC EDGAR · Schikan Johannes Gerardus Christiaan Petrus
Published Sep 24, 2026, 2:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 2:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PHVS
Neutral
high confidence
Mentioned
$PHVS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSNeutralLow
01

Why it matters

The disclosed sale is modest and does not suggest a change in insider confidence.

02

Market read

Small insider sale; limited relevance for traders.

03

Timing

filing date 2026-09-24

Relevance 3/10Novelty 4/10Timing: filing date 2026-09-24

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$PHVSNeutralHigh confidence
Context

Director Schikan sold 800 shares for $28,952, reducing his holdings to 115,167 shares.

Expected impact

minimal impact, price likely unchanged

Evidence & confidence

Sale size is small relative to float and no broader market implications.

Key entities

  • company
    Pharvaris N.V.

    Biotech company listed on Nasdaq under ticker PHVS.

  • person
    Schikan Johannes Gerardus Christiaan Petrus

    Director of Pharvaris who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PHVS insider trading history →

Related articles

SEP 12
$BCRXHigh

BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease

BioCryst Pharmaceuticals (BCRX) shares fell 9% on Tuesday, their worst day in over 6 months, after competitor Pharvaris (PHVS) reported positive late-stage trial results for a rare swelling disorder treatment. PHVS shares rose 7% during trading and 3% after-hours. Orladeyo, BioCryst's approved treatment, generated over $2B in revenue since 2020 and is expected to bring in $625M-$645M this year. BioCryst is also developing a second treatment, navenibart, with late-stage data expected in 2027.

stocktwits.com2 min
SEP 10
$PHVSMedAI 9/10

Pharvaris at Cantor Fitzgerald conference: oral HAE push gains momentum

Pharvaris (PHVS) presented at the Cantor Fitzgerald conference, highlighting 87% reduction in HAE attacks with deucrictibant in Phase III trials. The company plans an on-demand launch in April 2025 and a prophylaxis filing in the first half of 2025. Management addressed safety concerns and outlined a broad commercial strategy. Shares are up 62% over the past year, with analysts setting price targets between $42 and $79.

investing.com3 min
SEP 9
$PHVSHighAI 8/10

Wedbush Reaffirms Outperform Rating On Pharvaris; PT $42 After Positive Phase 3 CHAPTER-3 Data

Wedbush reaffirmed an Outperform rating and $42 price target for Pharvaris (PHVS) after positive Phase 3 data for deucrictibant XR in preventing hereditary angioedema attacks. The study met primary and secondary endpoints, showing an 83% reduction in attack rate. PHVS reported a Q2 2026 net loss of €47.8M and cash of €318M. The stock is up 7.35% on the day.

rttnews.com2 min